# Nuclide record abiraterone (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/abiraterone/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "abiraterone" ;
  schema:name "Abiraterone acetate"@en ;
  schema:description "Abiraterone is a pill that shuts down testosterone production everywhere, including inside the tumour. Discovered at the Institute of Cancer Research, now generic and used from the first metastatic diagnosis."@en ;
  schema:url <https://nuclide.cc/drugs/abiraterone/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Abiraterone_acetate> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27888393> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Abiraterone%20acetate> ;
  nuclide:status "approved" ;
  nuclide:modality "Small-molecule CYP17A1 inhibitor" ;
  schema:alternateName "Zytiga (generic)" ;
  nuclide:approval "US 2011: mCRPC after docetaxel", "US 2012: mCRPC pre-chemotherapy", "US 2018: High-risk mHSPC (LATITUDE)" ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mhspc/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/indications/prostate-high-risk/> ;
  nuclide:companies <https://nuclide.cc/companies/johnson-johnson/> ;
  nuclide:institutions <https://nuclide.cc/institutions/royal-marsden/> ;
  nuclide:trials <https://nuclide.cc/trials/stampede/>, <https://nuclide.cc/trials/nct06520345/>, <https://nuclide.cc/trials/nct07611110/> .